Kadimastem Ltd., a clinical stage cell therapy company, announced promising interim results of its Phase 1/2a clinical trial for the treatment of patients with ALS. The trial aims to evaluate the safety and preliminary efficacy of injecting AstroRx®, an “off-the-shelf” clinical-grade astrocyte cell product, into the spinal cord fluid of ALS patients. Click here to read the full article.
